Abstract
We have developed a strain of the tuberculosis vaccine Mycobacterium bovis bacille Calmette Guérin (BCG) that secretes high levels of a fusion protein comprising the immunodominant Mycobacterium tuberculosis Ag85B and ESAT-6 (BCG 85B-ES). Mice vaccinated with BCG 85B-ES were significantly better protected in the lung against aerosol infection with virulent M. tuberculosis than animals immunized with control BCG. The growth characteristic of BCG 85B-ES in host tissue was identical to control BCG, suggesting the improved protective efficacy was directly related to the expression of the Ag85B-ESAT-6 fusion protein. These results suggest that BCG 85B-ES warrants further investigation to determine its suitability to control tuberculosis in humans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
